Greenwich LifeSciences, Inc. (NASDAQ: GLSI) is a Healthcare company (Biotechnology) with a market capitalization of $241M. The Maz Rating grades it against the other companies in its sector.
Greenwich LifeSciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
Greenwich LifeSciences, Inc. has been loss-making over the last twelve months, so it has no meaningful P/E. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -1335.1%, return on invested capital of 1348.3% and a free cash flow yield of -6.3%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 0.77. Over the past 52 weeks the share price ranged from $7.78 to $34.10, with a beta of 1.55.
Greenwich LifeSciences, Inc. does not currently pay a dividend.
2 Wall Street analyst ratings cover the stock: 2 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.